PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?

被引:237
作者
Larsen, TM [1 ]
Toubro, S [1 ]
Astrup, A [1 ]
机构
[1] Royal Vet & Agr Univ, Res Dept Human Nutr, Copenhagen, Denmark
关键词
PPARgamma agonist; obesity; insulin resistance; long-term; thiazoledinediones;
D O I
10.1038/sj.ijo.802223
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The nuclear hormone receptor peroxisome proliferator-activated receptor gamma (PPARgamma) is a member of the PPAR family. The endogenous activators of all members of the PPAR family are a variety of fatty acids, which suggests that the PPARs are highly involved in lipid metabolism. In the present paper, the current understanding of the involvement of PPARgamma in adipocyte proliferation and adipose tissue formation is extensively reviewed, and it is stressed that PPARgamma seems to be a major regulator in the differentiation of adipocytes. Thiazoledinediones (TZDs) are a group of PPARgamma-agonists used in the treatment of type 2 diabetes (T2D) since 1997. They are characterized by their ability to decrease insulin resistance, and have been suggested to slow down the progression of insulin resistance. Treatment with TZD requires several weeks of treatment to decrease plasma glucose levels, but in addition they markedly decrease plasma triglycerides and free fatty acids. A major drawback of treatment with TZD is body fat gain, but some evidence suggests that the fat is redistributed in a favourable direction, that is, from visceral to subcutaneous depots. However, the effect of long-term treatment on weight gain following TZD treatment is unknown, and it may be questioned whether the use of these 'adipogenic compounds' is appropriate, considering that excess body fat is almost a prerequisite for the development of type 2 diabetes.
引用
收藏
页码:147 / 161
页数:15
相关论文
共 108 条
[1]   Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation [J].
Adams, M ;
Montague, CT ;
Prins, JB ;
Holder, JC ;
Smith, SA ;
Sanders, L ;
Digby, JE ;
Sewter, CP ;
Lazar, MA ;
Chatterjee, VKK ;
O'Rahilly, S .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (12) :3149-3153
[2]   Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site [J].
Adams, M ;
Reginato, MJ ;
Shao, DL ;
Lazar, MA ;
Chatterjee, VK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (08) :5128-5132
[3]   Efficacy of troglitazone on body fat distribution in type 2 diabetes [J].
Akazawa, S ;
Sun, FY ;
Ito, M ;
Kawasaki, E ;
Eguchi, K .
DIABETES CARE, 2000, 23 (08) :1067-1071
[4]   The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes [J].
Altshuler, D ;
Hirschhorn, JN ;
Klannemark, M ;
Lindgren, CM ;
Vohl, MC ;
Nemesh, J ;
Lane, CR ;
Schaffner, SF ;
Bolk, S ;
Brewer, C ;
Tuomi, T ;
Gaudet, D ;
Hudson, TJ ;
Daly, M ;
Groop, L ;
Lander, ES .
NATURE GENETICS, 2000, 26 (01) :76-80
[5]   Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes [J].
Arioglu, E ;
Duncan-Morin, J ;
Sebring, N ;
Rother, KI ;
Gottlieb, N ;
Lieberman, J ;
Herion, D ;
Kleiner, DE ;
Reynolds, J ;
Premkumar, A ;
Sumner, AE ;
Hoofnagle, J ;
Reitman, ML ;
Taylor, SI .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (04) :263-274
[6]   Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans - No alteration in adipose tissue of obese and NIDDM patients [J].
Auboeuf, D ;
Rieusset, J ;
Fajas, L ;
Vallier, P ;
Frering, V ;
Riou, JP ;
Staels, P ;
Auwerx, J ;
Laville, M ;
Vidal, H .
DIABETES, 1997, 46 (08) :1319-1327
[7]   PPARγ is required for placental, cardiac, and adipose tissue development [J].
Barak, Y ;
Nelson, MC ;
Ong, ES ;
Jones, YZ ;
Ruiz-Lozano, P ;
Chien, KR ;
Koder, A ;
Evans, RM .
MOLECULAR CELL, 1999, 4 (04) :585-595
[8]   Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension [J].
Barroso, I ;
Gurnell, M ;
Crowley, VEF ;
Agostini, M ;
Schwabe, JW ;
Soos, MA ;
Maslen, GL ;
Williams, TDM ;
Lewis, H ;
Schafer, AJ ;
Chatterjee, VKK ;
O'Rahilly, S .
NATURE, 1999, 402 (6764) :880-883
[9]   Alterations of peroxisome proliferator-activated receptor δ activity affect fatty acid-controlled adipose differentiation [J].
Bastie, C ;
Luquet, S ;
Holst, D ;
Jehl-Pietri, C ;
Grimaldi, PA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (49) :38768-38773
[10]   Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-γ2 gene with obesity in two Caucasian populations [J].
Beamer, BA ;
Yen, CJ ;
Andersen, BE ;
Muller, D ;
Elahi, D ;
Cheskin, LJ ;
Andres, R ;
Roth, J ;
Shuldiner, AR .
DIABETES, 1998, 47 (11) :1806-1808